Stifel Downgrades Fate Therapeutics (FATE ) to Hold
Tweet
Share
E-mailGet Alerts FATE Hot Sheet
Price: $2.65 --0%
Rating Summary:
11 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 9
Rating Summary:
11 Buy, 13 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 9
Join SI Premium – FREE
Stifel analyst Benjamin Burnett downgraded Fate Therapeutics (NASDAQ: FATE ) from Buy to Hold with a price target of $5.30 (from $107.00).
For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.
Shares of Fate Therapeutics closed at $11.00 yesterday.
You May Also Be Interested In
- Citi cuts TJX Companies rating to Neutral, lowers price target
- Snowflake Inc. (SNOW) PT Raised to $370 at TD Cowen
- Evolution Mining Ltd. (EVN:AU) (CAHPF) PT Raised to AUD13.60 at UBS
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
